Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZEST niraparib versus placebo in molecular residual disease-positive breast cancer
2020-003973-23Phase 3Completed
- Sponsor
- GSK
- Start
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in breast cancer and triple-negative breast cancer (TNBC) comparing Niraparib with Placebo (2 arms). Primary endpoint: Disease-free survival. Started Mar 2021; status: completed.
02
Drugs
niraparib
03
Conditions
breast cancertriple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on 2020-003973-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003973-23.